Everything below concerns Immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
=== Cardiac === The collagenous cardiac skeleton, which includes the four heart valve rings, is histologically, elastically and uniquely bound to cardiac muscle. The cardiac skeleton also includes the separating septa of the heart chambers – the interventricular septum and the atrioventricular septum. Collagen contribution to the measure of cardiac performance summarily represents a continuous torsional force opposed to the fluid mechanics of blood pressure emitted from the heart. The collagenous structure that divides the upper chambers of the heart from the lower chambers is an impermeable membrane that excludes both blood and electrical impulses through typical physiological means. With support from collagen, atrial fibrillation never deteriorates to ventricular fibrillation. Collagen is layered in variable densities with smooth muscle mass. The mass, distribution, age, and density of collagen all contribute to the compliance required to move blood back and forth. Individual cardiac valvular leaflets are folded into shape by specialized collagen under variable pressure. Gradual calcium deposition within collagen occurs as a natural function of aging. Calcified points within collagen matrices show contrast in a moving display of blood and muscle, enabling methods of cardiac imaging technology to arrive at ratios essentially stating blood in (cardiac input) and blood out (cardiac output). Pathology of the collagen underpinning of the heart is understood within the category of connective tissue disease.
Transcription of mRNA: Synthesis begins with turning on genes associated with the formation of a particular alpha peptide (typically alpha 1, 2 or 3). About 45 genes are associated with collagen formation, each coding for a specific mRNA sequence, and are typically named with the "COL" prefix. These 45 genes encode the 28 collagen types described in vertebrates. Pre-pro-peptide formation: The created mRNA exits the cell nucleus into the cytoplasm. There, it links with the ribosomal subunits and is translated into a peptide. The peptide goes into the endoplasmic reticulum for post-translational processing. It is directed there by a signal recognition particle on the endoplasmic reticulum, which recognizes the peptide's N-terminal signal sequence (the early part of the sequence). The processed product is a pre-pro-peptide called preprocollagen. Pro-collagen formation: Three modifications of the pre-pro-peptide form the alpha peptide: The signal peptide on the N-terminal is removed. This molecule is called 'propeptide.' Lysines and prolines are hydroxylated by the enzymes 'prolyl hydroxylase' and 'lysyl hydroxylase', producing hydroxyproline and hydroxylysine. This helps in cross-linking the alpha peptides. This enzymatic step requires vitamin C as a cofactor. In scurvy, the lack of hydroxylation of prolines and lysines causes a looser triple helix (which is formed by three alpha peptides). Glycosylation occurs by adding either glucose or galactose monomers onto the hydroxyl groups that were placed onto lysines, but not on prolines.
The second edition in the Retro series was a collection of "Making of" features, most of which had run previously in the main magazine. These features usually contained interviews with the makers of classic video games talking about the process involved in their title's creation. "Edge presents Equip: PlayStation 2 edition" "Edge presents Equip: GameCube edition" "Edge presents Equip: PC edition" "Edge presents Equip: Xbox edition"
Sources: en.wikipedia.org
For even higher stresses, materials exhibit plastic behavior, that is, they deform irreversibly and do not return to their original shape after stress is no longer applied. For rubber-like materials such as elastomers, the slope of the stress–strain curve increases with stress, meaning that rubbers progressively become more difficult to stretch, while for most metals, the gradient decreases at very high stresses, meaning that they progressively become easier to stretch. Elasticity is not exhibited only by solids; non-Newtonian fluids, such as viscoelastic fluids, will also exhibit elasticity in certain conditions quantified by the Deborah number. In response to a small, rapidly applied and removed strain, these fluids may deform and then return to their original shape. Under larger strains, or strains applied for longer periods of time, these fluids may start to flow like a viscous liquid. Because the elasticity of a material is described in terms of a stress–strain relation, it is essential that the terms stress and strain be defined without ambiguity. Typically, two types of relation are considered. The first type deals with materials that are elastic only for small strains. The second deals with materials that are not limited to small strains. Clearly, the second type of relation is more general in the sense that it must include the first type as a special case.
=== Periodontal regeneration === Reproduction or reconstitution of a lost or injured part to restore the architecture and function of the periodontium becomes the integral part of comprehensive periodontal therapy. Conventional open flap debridement falls short of regenerating tissues destroyed by the disease. Platelet derived growth factor along with bone morphogenetic proteins are among the most researched growth factors in periodontal regeneration. Platelet rich fibrin showed significant improvement in clinical periodontal parameter as well as in radiograph when compared with open flap debridement alone in a meta analysis. Several bone graft materials have been used in the treatment of infrabony defects. Demineralized freeze dried bone allograft (DFDBA) has been histologically proven to be the material of choice for regeneration. Platelet-rich fibrin has shown significant results comparable to DFDBA for periodontal regeneration. One of the most common aesthetic problem encountered in the field of periodontology is gingival recession, which is perceived by the patients as increase in length of teeth. Though connective tissue graft is a gold standard procedure, PRF can be used as an alternative procedure by keeping patient's comfort in mind.
=== Sepsis === IGFBP-3 has been implicated in the regulation of cell growth, immune response, and endothelial integrity. In patients with sepsis, reduced serum levels of IGFBP-3 have been associated with increased mortality and greater immune suppression. A 2025 prospective study on 139 patients with microbiologically confirmed sepsis found that baseline IGFBP-3 concentrations below 10.64 pg/mL were independently associated with higher 30-day (28% vs. 10%) and 1-year mortality (69% vs. 35%) compared to patients with higher levels. These patients also exhibited lower lymphocyte counts, increased interleukin-6 levels, and more frequent polymicrobial infections, suggesting a phenotype characterized by immunosuppression and gut barrier dysfunction. IGFBP-3 had an area under the ROC curve (AUROC) of 0.70 for predicting 1-year mortality, outperforming other biomarkers such as CRP, procalcitonin, IL-6, and lactate. When added to clinical models including age and SOFA score, IGFBP-3 significantly improved prognostic accuracy up to 365 days. Preclinical studies support its immunomodulatory and anti-apoptotic roles, and therapeutic strategies targeting the IGF-1/IGFBP-3 axis are under investigation.
Sources: en.wikipedia.org
== Heuristic Dendral == Heuristic Dendral is a program that uses mass spectra or other experimental data together with a knowledge base of chemistry to produce a set of possible chemical structures that may be responsible for producing the data. A mass spectrum of a compound is produced by a mass spectrometer, and is used to determine its molecular weight, the sum of the masses of its atomic constituents. For example, the compound water (H2O), has a molecular weight of 18 since hydrogen has a mass of 1.01 and oxygen 16.00, and its mass spectrum has a peak at 18 units. Heuristic Dendral would use this input mass and the knowledge of atomic mass numbers and valence rules, to determine the possible combinations of atomic constituents whose mass would add up to 18. As the weight increases and the molecules become more complex, the number of possible compounds increases drastically. Thus, a program that is able to reduce this number of candidate solutions through the process of hypothesis formation is essential. New graph-theoretic algorithms were invented by Lederberg, Harold Brown, and others that generate all graphs with a specified set of nodes and connection-types (chemical atoms and bonds) -- with or without cycles. Moreover, the team was able to prove mathematically that the generator is complete, in that it produces all graphs with the specified nodes and edges, and that it is non-redundant, in that the output contains no equivalent graphs (e.g., mirror images).
== Side effects == Like ketamine, etoxadrol produces increases in heart rate and respiratory rate. Etoxadrol may also cause vomiting. At high enough doses, etoxadrol also exhibits effects on the muscular system such as convulsions or loss of the righting reflex. When administered in excess, etoxadrol can be lethal on the respiratory system. Monkeys given extremely high (> 20 mg/kg) doses of etoxadrol died of apparent respiratory failure. Etoxadrol produces a wide variety of dreams, ranging from pleasant to frightening or aversive. Approximately half of patients given etoxadrol report pleasant dreams, 25% report unpleasant dreams, and the remaining 25% experience no dreams at all. Such dreams were frequently described as “floating,” “puffy” or “out of this world." Dreams and hallucinations may persist for as long as 18 to 24 hours. In rare cases, etoxadrol can induce periods of psychotic activity during this recovery period. In the brain, etoxadrol slows down the synthesis of serotonin to 50-60% of control rates and speeds up the rate of dopamine synthesis by up to 200% of the normal rate 4–6 hours after intravenous administration. Like a number of other drugs (e.g. cocaine), etoxadrol has been found to exhibit reinforcing properties. Monkeys will self-administer etoxadrol, dexoxadrol or PCP in a lever-pressing paradigm.
Action Game – Half-Life 2 Animation – Half-Life 2 Art Direction – Half-Life 2 Audio Achievement – Call of Duty: Finest Hour Best Game – Half-Life 2 Children's – Donkey Konga GameCube – Prince of Persia: Warrior Within Handheld – Colin McRae Rally 2005 Mobile Game – BlueTooth BiPlanes Online Multiplayer – Half-Life 2 Original Music – Hitman: Contracts Originality – SingStar/Singstar Party PC – Half-Life 2 PS2 – Burnout 3: Takedown Racing – Burnout 3: Takedown Sports – Pro Evolution Soccer 4 Sunday Times Reader Award for Games – Football Manager 2005 Technical Direction – Burnout 3: Takedown Xbox – Halo 2 Special Award (Games) – Sam Houser & Leslie Benzies
=== Urothelial lesions === Papillary urothelial lesions Papillary urothelial hyperplasia Urothelial papilloma Papillary urothelial neoplasm of low malignant potential (PUNLMP) Low-grade papillary urothelial carcinoma High-grade papillary urothelial carcinoma Invasive urothelial carcinoma Flat urothelial lesions Reactive urothelial atypia Urothelial inverted papilloma Urothelial atypia of unknown significance Urothelial dysplasia Urothelial carcinoma in situ Invasive urothelial carcinoma Invasive urothelial carcinoma (NOS) Urothelial carcinoma with inverted growth pattern Urothelial carcinoma with squamous differentiation Urothelial carcinoma with villoglandular differentiation Urothelial carcinoma, micropapillary variant Urothelial carcinoma, lymphoepithelioma-like variant Urothelial carcinoma, clear cell (glycogen-rich) variant Urothelial carcinoma, lipoid cell variant Urothelial carcinoma with syncitiotrophoblastic giant cells Urothelial carcinoma with rhabdoid differentiation Urothelial carcinoma similar to giant cell tumor of bone
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.